Click on a filter below to refine your search. Remove a filter to broaden your search.
The ceiling prices for negotiation would have reduced Medicare prescription drug spending by ~5% if implemented from 2018 to 2020.
From 2007 to 2019, the medical burden increased from 23.5 to 26.4% for low-income families and from 5.4 to 6.5% for higher-income families.
National health expenditures are projected to have increased 7.5% in 2023, when the COVID-19 public health emergency ended.
Wearing surgical face mask in public over 14 days reduces risk for self-reported symptoms consistent with respiratory infection
Under the law, Medicare will now be allowed to negotiate the cost of some drugs, and vaccines will be free for Part D recipients.
For the first time, the measure would enable the federal government to negotiate prices for medications covered by Medicare.
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
Less effect among those who lived in poor-quality neighborhoods suggested in exploratory analysis.
An increase of 5.4% is projected per year, and expenditures are set to account for about 20% of GDP in 2031.
Ten drugs have been chosen for price negotiations by the Centers for Medicare & Medicaid Services.